Related references
Note: Only part of the references are listed.Emricasan to prevent new decompensation in patients with NASH-related decompensated cirrhosis
Catherine Frenette et al.
JOURNAL OF HEPATOLOGY (2021)
AGA Clinical Practice Update on Lifestyle Modification Using Diet and Exercise to Achieve Weight Loss in the Management of Nonalcoholic Fatty Liver Disease: Expert Review
Zobair M. Younossi et al.
GASTROENTEROLOGY (2021)
Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention
Daniel Q. Huang et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2021)
Review article: The impact of liver-directed therapies on the atherogenic risk profile in non-alcoholic steatohepatitis
Margery A. Connelly et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2020)
Bariatric Surgery Provides Long-term Resolution of Nonalcoholic Steatohepatitis and Regression of Fibrosis
Guillaume Lassailly et al.
GASTROENTEROLOGY (2020)
Upregulation of BDNF and hippocampal functions by a hippocampal ligand of PPARα
Dhruv Patel et al.
JCI INSIGHT (2020)
Identification of p115 as a novel ACSL4 interacting protein and its role in regulating ACSL4 degradation
Progga Sen et al.
JOURNAL OF PROTEOMICS (2020)
Silencing hepatic MCJ attenuates non-alcoholic fatty liver disease (NAFLD) by increasing mitochondrial fatty acid oxidation
Lucia Barbier-Torres et al.
NATURE COMMUNICATIONS (2020)
TANK-Binding Kinase 1 Regulates the Localization of Acyl-CoA Synthetase ACSL1 to Control Hepatic Fatty Acid Oxidation
Jin Young Huh et al.
CELL METABOLISM (2020)
Ischemia-induced ACSL4 activation contributes to ferroptosis-mediated tissue injury in intestinal ischemia/reperfusion
Yang Li et al.
CELL DEATH AND DIFFERENTIATION (2019)
Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease
Laurent Castera et al.
GASTROENTEROLOGY (2019)
Metabolic aspects in NAFLD, NASH and hepatocellular carcinoma: the role of PGC1 coactivators
Elena Piccinin et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2019)
Multiomics Profiling Establishes the Polypharmacology of FDA-Approved CDK4/6 Inhibitors and the Potential for Differential Clinical Activity
Marc Hafner et al.
CELL CHEMICAL BIOLOGY (2019)
CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought
Mary E. Klein et al.
CANCER CELL (2018)
Squalene epoxidase drives NAFLD-induced hepatocellular carcinoma and is a pharmaceutical target
Dabin Liu et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
A role for long-chain acyl-CoA synthetase-4 (ACSL4) in diet-induced phospholipid remodeling and obesity-associated adipocyte dysfunction
Elizabeth A. Killion et al.
MOLECULAR METABOLISM (2018)
Abemaciclib Is Active in Preclinical Models of Ewing Sarcoma via Multipronged Regulation of Cell Cycle, DNA Methylation, and Interferon Pathway Signaling
Michele Dowless et al.
CLINICAL CANCER RESEARCH (2018)
ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition
Sebastian Doll et al.
NATURE CHEMICAL BIOLOGY (2017)
Targeting CDK4 and CDK6: From Discovery to Therapy
Charles J. Sherr et al.
CANCER DISCOVERY (2016)
Nonalcoholic Fatty Liver Disease: Pathogenesis and Disease Spectrum
Timothy Hardy et al.
ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 11 (2016)
Targeting CDK4/6 in patients with cancer
Erika Hamilton et al.
CANCER TREATMENT REVIEWS (2016)
Liver PPARα is crucial for whole-body fatty acid homeostasis and is protective against NAFLD
Alexandra Montagner et al.
GUT (2016)
Identification and characterization of PPARα ligands in the hippocampus
Avik Roy et al.
NATURE CHEMICAL BIOLOGY (2016)
Role of long-chain acyl-CoA synthetase 4 in formation of polyunsaturated lipid species in hepatic stellate cells
Maidina Tuohetahuntila et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS (2015)
Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis
Eduardo Vilar-Gomez et al.
GASTROENTEROLOGY (2015)
Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease
Michal Pawlak et al.
JOURNAL OF HEPATOLOGY (2015)
Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis
Anabela P. Rolo et al.
FREE RADICAL BIOLOGY AND MEDICINE (2012)
Protection from Obesity and Diabetes by Blockade of TGF-β/Smad3 Signaling
Hariom Yadav et al.
CELL METABOLISM (2011)
Randomized Controlled Trial Testing the Effects of Weight Loss on Nonalcoholic Steatohepatitis
Kittichai Promrat et al.
HEPATOLOGY (2010)
Genetic variation in the ADIPOR2 gene is associated with liver fat content and its surrogate markers in three independent cohorts
Anna Kotronen et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2009)
Genes involved in fatty acid partitioning and binding, lipolysis, monocyte/macrophage recruitment, and inflammation are overexpressed in the human fatty liver of insulin-resistant subjects
Jukka Westerbacka et al.
DIABETES (2007)
Lipin 1 is an inducible amplifier of the hepatic PGC-1α/PPARα regulatory pathway
Brian N. Finck et al.
CELL METABOLISM (2006)
Long-term weight loss maintenance
RR Wing et al.
AMERICAN JOURNAL OF CLINICAL NUTRITION (2005)
Plasma transforming growth factor-β1 level and efficacy of α-tocopherol in patients with non-alcoholic steatohepatitis:: a pilot study
T Hasegawa et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2001)
Metformin in non-alcoholic steatohepatitis
G Marchesini et al.
LANCET (2001)
Expression and characterization of recombinant rat acyl-CoA synthetases 1, 4, and 5 - Selective inhibition by triacsin C and thiazolidinediones
JH Kim et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Share Paper
